Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...
Clinicopathological factors related to survival in gastroenteropancreatic neuroendocrine tumors (GEP-NET): 20 years experience in the American British Cowdray Medical Center. This is an ASCO Meeting ...
At the final analysis of the study, Cabometyx reduced the risk of progression or death by 77% compared with placebo in patients with heavily pretreated advanced pancreatic neuroendocrine tumors ...
Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...
WTEN Albany on MSN3d
‘Every week is a gift:’ Why Saratoga cancer survivor holds hopeWorld Cancer Day recognizes the millions of people affected by cancer each and every day. One cancer survivor in Saratoga ...
After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...
Hosted on MSN20d
What Is Pancreatic Cancer?There are two main types of pancreatic cancer, based on the type of cell that the tumor develops in. The two main types are exocrine and neuroendocrine. About 93% of pancreatic cancer cases begin ...
T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited ... M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and ...
Exelixis (EXEL) announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback